Skip to main content
Top
Published in: Endocrine 2/2018

01-05-2018 | Clinical Management of Endocrine Diseases

Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study

Authors: S. Chiloiro, F. Lanza, A. Bianchi, G. Schinzari, M. G. Brizi, A. Giampietro, V. Rufini, F. Inzani, A. Giordano, G. Rindi, A. Pontecorvi, L. De Marinis

Published in: Endocrine | Issue 2/2018

Login to get access

Abstract

Purpose

Multiple endocrine neoplasia type 1 (MEN1) is an inherited endocrine neoplastic syndrome associated with a greater risk of endocrine tumor development like pancreatic neuroendocrine tumors (p-NET), with different clinical characteristics from sporadic ones. This paper aims to compare clinical, hystological and morphological aspects of p-NET in patients affected from MEN1 (MEN1+) and not-affected ones (MEN1−).

Methods

We performed a retrospective observational study. Data was collected between December 2010 and December 2015, including patients with a histological diagnosis of p-NET and radiological imaging. We compared clinical, histological, radiological, and prognostic aspects of MEN+ p-NET with MEN−1 p-NET.

Results

Of the 45 patients enrolled, 13 MEN1+ and 21 MEN1− cases were analyzed. Frequency of not secreting p-NETs and insulin secreting p-NETs, histopathological grades and Ki67 expression were superimposable between MEN1+ and MEN1− patients. MEN1+ pNETs are more often multicentric compared to MEN1− pNETs. Frequency of liver and nodes metastatic spread was higher in MEN1− p-NET compared to MEN1+ p-NET. Analyzing p-NET according to the disease outcome, we found that recovered and stable p-NETs in MEN1+ patients, compared to MEN1− cases, are diagnosed at lower age (p = 0.04/p = 0.002) and that are more frequently multifocal lesions (p = 0.009/p = 0.002).

Conclusions

In our study pNETs in MEN1+ and pNETs in MEN1− don’t significantly differ for prognosis but only for clinical features. p-NET stage disease and prognosis can be positively influenced by early diagnosis and screening in index patients’ first-degree relatives
Literature
1.
2.
go back to reference P. Wermer, Endocrine adenomatosis, peptic ulcer disease in a large kindred: inherited multiple tumors, mosaic pleiotropism in man. Am. J. Med. 35, 205–208 (1963)CrossRefPubMed P. Wermer, Endocrine adenomatosis, peptic ulcer disease in a large kindred: inherited multiple tumors, mosaic pleiotropism in man. Am. J. Med. 35, 205–208 (1963)CrossRefPubMed
3.
go back to reference A. Sakurai, S. Suzuki, S. Kosugi, T. Okamoto, S. Uchino, A. Miya et al., Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of multicenter database. Clin. Endocrinol. 76(4), 533–539 (2012)CrossRef A. Sakurai, S. Suzuki, S. Kosugi, T. Okamoto, S. Uchino, A. Miya et al., Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of multicenter database. Clin. Endocrinol. 76(4), 533–539 (2012)CrossRef
4.
go back to reference J.M. Glascock, S.E. Carty, Multiple endocrine neoplasia type 1: fresh perspective on clinical features and penetrance. Surg. Oncol. 11, 143–150 (2002)CrossRefPubMed J.M. Glascock, S.E. Carty, Multiple endocrine neoplasia type 1: fresh perspective on clinical features and penetrance. Surg. Oncol. 11, 143–150 (2002)CrossRefPubMed
5.
go back to reference S.L. Dʼsouza, B.J. Elmunzer, J.M. Scheiman, Long-term follow-up of asymptomatic pancreatic neuroendocrine tumors in multiple endocrine neoplasia type I syndrome. J. Clin. Gastroenterol. 48(5), 458–461 (2014)PubMed S.L. Dʼsouza, B.J. Elmunzer, J.M. Scheiman, Long-term follow-up of asymptomatic pancreatic neuroendocrine tumors in multiple endocrine neoplasia type I syndrome. J. Clin. Gastroenterol. 48(5), 458–461 (2014)PubMed
6.
go back to reference F. Gibril, D.J. Venzon, J.V. Ojeburu, S. Bashir, R.T. Jensen, Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J. Clin. Endocrinol. Metab. 86(11), 5282–5293 (2001)CrossRefPubMed F. Gibril, D.J. Venzon, J.V. Ojeburu, S. Bashir, R.T. Jensen, Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J. Clin. Endocrinol. Metab. 86(11), 5282–5293 (2001)CrossRefPubMed
7.
go back to reference G. Åkerström, O. Hessman, B. Skogseid, Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbeck’s Arch Surg 386, 558–569 (2002)CrossRef G. Åkerström, O. Hessman, B. Skogseid, Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbeck’s Arch Surg 386, 558–569 (2002)CrossRef
8.
go back to reference G. Rindi, R. Arnold, C. Capella, et al. in Nomenclature and Classification of Neuroendocrine Neoplasms of the Digestive System, ed. by F. Bosman, F. Carneiro. World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of the Digestive System (Lyon, IARC Press, 2010), p. 10–12. G. Rindi, R. Arnold, C. Capella, et al. in Nomenclature and Classification of Neuroendocrine Neoplasms of the Digestive System, ed. by F. Bosman, F. Carneiro. World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of the Digestive System (Lyon, IARC Press, 2010), p. 10–12.
9.
go back to reference G. Klöppel, G. Rindi, A. Perren, P. Komminoth, D.S. Klimstra, The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows. Arch. 456, 595–597 (2010)CrossRefPubMed G. Klöppel, G. Rindi, A. Perren, P. Komminoth, D.S. Klimstra, The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows. Arch. 456, 595–597 (2010)CrossRefPubMed
10.
go back to reference R.V. Thakker, P.J. Newey, G.V. Walls, J. Bilezikian, H. Dralle, P.R. Ebeling, S. Melmed, A. Sakurai, F. Tonelli, M.L. Brandi, Clinical practice guidelines for multiple endocrine Neoplasia type 1 (MEN1). J. Clin. Endocrinol. Metab. 97, 2990–3011 (2012)CrossRefPubMed R.V. Thakker, P.J. Newey, G.V. Walls, J. Bilezikian, H. Dralle, P.R. Ebeling, S. Melmed, A. Sakurai, F. Tonelli, M.L. Brandi, Clinical practice guidelines for multiple endocrine Neoplasia type 1 (MEN1). J. Clin. Endocrinol. Metab. 97, 2990–3011 (2012)CrossRefPubMed
11.
go back to reference A. Zerbi, M. Falconi, G. Rindi, G. Delle Fave, P. Tomassetti, C. Pasquali, V. Capitanio, L. Boninsegna, V. Di Carlo; the members of the AISP-Network Study Group, Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 Sporadic Cases. Am. J. Gastroenterol. 105, 1421–1429 (2010)CrossRefPubMed A. Zerbi, M. Falconi, G. Rindi, G. Delle Fave, P. Tomassetti, C. Pasquali, V. Capitanio, L. Boninsegna, V. Di Carlo; the members of the AISP-Network Study Group, Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 Sporadic Cases. Am. J. Gastroenterol. 105, 1421–1429 (2010)CrossRefPubMed
12.
go back to reference A. Zerbi, V. Capitanio, L. Boninsegna, G. Delle Fave, C. Pasquali, G. Rindi, D. Campana, M. Falconi; the members of the AISP-Network Study Group, Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. HPB 15, 935–943 (2013)CrossRefPubMedPubMedCentral A. Zerbi, V. Capitanio, L. Boninsegna, G. Delle Fave, C. Pasquali, G. Rindi, D. Campana, M. Falconi; the members of the AISP-Network Study Group, Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. HPB 15, 935–943 (2013)CrossRefPubMedPubMedCentral
13.
go back to reference P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, L. Rubinstein et al., New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92, 205–216 (2000)CrossRefPubMed P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, L. Rubinstein et al., New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92, 205–216 (2000)CrossRefPubMed
14.
go back to reference B. Skögseid, J. Rastad, G. Akerström. Pancreatic Endocrine Tumors in Multiple Endocrine Neo- plasia Type 1. Surgical Endocrinology, ed. by G.M. Doherty, B. Skögseid (Lippincott, Williams & Wilkins, Philadelphia, 2001) p. 510–524 B. Skögseid, J. Rastad, G. Akerström. Pancreatic Endocrine Tumors in Multiple Endocrine Neo- plasia Type 1. Surgical Endocrinology, ed. by G.M. Doherty, B. Skögseid (Lippincott, Williams & Wilkins, Philadelphia, 2001) p. 510–524
15.
go back to reference R.T. Jensen. Zollinger-Ellison syndrome. Surgical Endocrinology, ed. by G.M. Doherty, B. Skögseid (Lippincott, Williams & Wilkins, Philadelphia, 2001) 291–344 R.T. Jensen. Zollinger-Ellison syndrome. Surgical Endocrinology, ed. by G.M. Doherty, B. Skögseid (Lippincott, Williams & Wilkins, Philadelphia, 2001) 291–344
16.
go back to reference K. Hanazaki, A. Sakurai, M. Munekage, K. Ichikawa, T. Namikawa, T. Okabayashi, M. Imamura, Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1. Surg. Today 43(3), 229–236 (2013)CrossRefPubMed K. Hanazaki, A. Sakurai, M. Munekage, K. Ichikawa, T. Namikawa, T. Okabayashi, M. Imamura, Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1. Surg. Today 43(3), 229–236 (2013)CrossRefPubMed
17.
go back to reference F. Tonelli, F. Giudici, G. Fratini, M.L. Brandi, Pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: review of literature. Endocr. Pract. 17(suppl 3), 33–40 (2011) F. Tonelli, F. Giudici, G. Fratini, M.L. Brandi, Pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: review of literature. Endocr. Pract. 17(suppl 3), 33–40 (2011)
18.
go back to reference P.V. Dickson, T.A. Rich, Y. Xing, G.J. Cote, H. Wang, N.D. Perrier et al., Achieving eugastrinemia in MEN1 patients: both duodenal inspection and formal lymph node dissection are important. Surgery 150, 1143–1152 (2011)CrossRefPubMed P.V. Dickson, T.A. Rich, Y. Xing, G.J. Cote, H. Wang, N.D. Perrier et al., Achieving eugastrinemia in MEN1 patients: both duodenal inspection and formal lymph node dissection are important. Surgery 150, 1143–1152 (2011)CrossRefPubMed
19.
go back to reference M.L. Brandi, R.F. Gagel, A. Angeli, J.P. Bilezikian, P. Beck-Peccoz, C. Bordi, B. Conte-Devolx, A. Falchetti, R.G. Gheri, A. Libroia, C.J.M. Lips, G. Lombardi, M. Mannelli, F. Pacini, B.A.J. Ponder, F. Raue, B. Skogseid, G. Tamburrano, R.V. Thakker, N.W. Thompson, P. Tomassetti, F. Tonelli, S.A. Wells, Jr., S.J. Marx, Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86(12), 5658–5671 (2001) M.L. Brandi, R.F. Gagel, A. Angeli, J.P. Bilezikian, P. Beck-Peccoz, C. Bordi, B. Conte-Devolx, A. Falchetti, R.G. Gheri, A. Libroia, C.J.M. Lips, G. Lombardi, M. Mannelli, F. Pacini, B.A.J. Ponder, F. Raue, B. Skogseid, G. Tamburrano, R.V. Thakker, N.W. Thompson, P. Tomassetti, F. Tonelli, S.A. Wells, Jr., S.J. Marx, Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86(12), 5658–5671 (2001)
20.
go back to reference M. Vázquez, S. Muñoz, L. López, C. Hernández, J. Navalón, Diagnostic/therapeutic management of pancreatic neuroendocrine tumours associated with MEN 1 syndrome. Cir. Esp. 93(8), 539–541 (2015)CrossRef M. Vázquez, S. Muñoz, L. López, C. Hernández, J. Navalón, Diagnostic/therapeutic management of pancreatic neuroendocrine tumours associated with MEN 1 syndrome. Cir. Esp. 93(8), 539–541 (2015)CrossRef
21.
go back to reference F. Triponez, D. Dosseh, P. Goudet et al., Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann. Surg. 243, 265–272 (2006)CrossRefPubMedPubMedCentral F. Triponez, D. Dosseh, P. Goudet et al., Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann. Surg. 243, 265–272 (2006)CrossRefPubMedPubMedCentral
22.
go back to reference R.B. Lewis, G.E. Lattin Jr., E. Paal, Endocrine tumors: Radiologic- clinicopathologic correlation. Radiographics 30(6), 1445–1464 (2010)CrossRefPubMed R.B. Lewis, G.E. Lattin Jr., E. Paal, Endocrine tumors: Radiologic- clinicopathologic correlation. Radiographics 30(6), 1445–1464 (2010)CrossRefPubMed
23.
go back to reference L. Boninsegna, S. Partelli, M.M. D’Innocenzio, P. Capelli, A. Scarpa, C. Bassi, P. Pederzoli, M. Falconi, Pancreatic cystic endocrine tumors: a different morphological entity associated with a less aggressive behavior. Neuroendocrinology 92(4), 246–251 (2010)CrossRefPubMed L. Boninsegna, S. Partelli, M.M. D’Innocenzio, P. Capelli, A. Scarpa, C. Bassi, P. Pederzoli, M. Falconi, Pancreatic cystic endocrine tumors: a different morphological entity associated with a less aggressive behavior. Neuroendocrinology 92(4), 246–251 (2010)CrossRefPubMed
25.
go back to reference U. Plöckinger, B. Wiedenman, Neuroendocrine tumors of the gastro-entero-pancreatic system: the role of early diagnosis, genetic testing and preventive surgery. Dig. Dis. 20, 49–60 (2002)CrossRefPubMed U. Plöckinger, B. Wiedenman, Neuroendocrine tumors of the gastro-entero-pancreatic system: the role of early diagnosis, genetic testing and preventive surgery. Dig. Dis. 20, 49–60 (2002)CrossRefPubMed
26.
go back to reference K. Drbalová, K. Herdová, P. Krejčí, M. Nývltová, S. Solař, L. Vedralová, P. Záruba, D. Netuka, P. Bavor, [Multiple Endocrine Neoplasia I (Wermers Syndrome), Forms of Clinical Manifestation, 5 Case Studies]. Vnitr. Lek. 62(Suppl 3), 140–149 (2016)PubMed K. Drbalová, K. Herdová, P. Krejčí, M. Nývltová, S. Solař, L. Vedralová, P. Záruba, D. Netuka, P. Bavor, [Multiple Endocrine Neoplasia I (Wermers Syndrome), Forms of Clinical Manifestation, 5 Case Studies]. Vnitr. Lek. 62(Suppl 3), 140–149 (2016)PubMed
27.
go back to reference M.S. Hausman, Jr., N.W. Thompson, P.G. Gauger, G.M. Doherty, The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. Surgery 136, 1205–1211 (2004) M.S. Hausman, Jr., N.W. Thompson, P.G. Gauger, G.M. Doherty, The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. Surgery 136, 1205–1211 (2004)
28.
go back to reference T. Ito, H. Sasano, M. Tanaka, R.Y. Osamura, I. Sasaki et al., Epidemiological study of gastroenteropan- creatic neuroendocrine tumors in Japan. J. Gastroenterol. 45, 234–243 (2010)CrossRefPubMed T. Ito, H. Sasano, M. Tanaka, R.Y. Osamura, I. Sasaki et al., Epidemiological study of gastroenteropan- creatic neuroendocrine tumors in Japan. J. Gastroenterol. 45, 234–243 (2010)CrossRefPubMed
29.
go back to reference R. Casadei, C. Ricci, R. Pezzilli, D. Campana, P. Tomassetti, L. Calculli, D. Santini, M. D’Ambra, F. Minni, Are there prognostic factors related to recurrence in pancreatic endocrine tumors? Pancreatology 10(1), 33–38 (2010)CrossRefPubMed R. Casadei, C. Ricci, R. Pezzilli, D. Campana, P. Tomassetti, L. Calculli, D. Santini, M. D’Ambra, F. Minni, Are there prognostic factors related to recurrence in pancreatic endocrine tumors? Pancreatology 10(1), 33–38 (2010)CrossRefPubMed
30.
go back to reference D. Granberg, M. Stridsberg, R. Seensalu, B. Eriksson, G. Lundqvist, K.O ̈ Berg, B. Skogseid, Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. CE & M. 84, (8), 2712–2717 (1999) D. Granberg, M. Stridsberg, R. Seensalu, B. Eriksson, G. Lundqvist, K.O ̈ Berg, B. Skogseid, Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. CE & M. 84, (8), 2712–2717 (1999)
31.
go back to reference I.M. Modlin, B.I. Gustafsson, S.F. Moss, M. Pavel, A.V. Tsolakis, M. Kidd, Chromogranin A—Biological function and clinical utility in neuro endocrine tumor disease. Ann. Surg. Oncol. 17, 2427–2443 (2010)CrossRefPubMed I.M. Modlin, B.I. Gustafsson, S.F. Moss, M. Pavel, A.V. Tsolakis, M. Kidd, Chromogranin A—Biological function and clinical utility in neuro endocrine tumor disease. Ann. Surg. Oncol. 17, 2427–2443 (2010)CrossRefPubMed
32.
go back to reference B. Lawrence, B.I. Gustafsson, M. Kidd, M. Pavel, B. Svejda, I.M. Modlin, The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am 40, 111–134 (2011)CrossRef B. Lawrence, B.I. Gustafsson, M. Kidd, M. Pavel, B. Svejda, I.M. Modlin, The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am 40, 111–134 (2011)CrossRef
33.
go back to reference E. Bajetta, L. Ferrari, A. Martinetti, L. Celio, G. Procopio, S. Artale, N. Zilembo, M. Di Bartolomeo, E. Seregni, E. Bombardieri, Chromogranin A., neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer, 86(5), 858–865 (1999) E. Bajetta, L. Ferrari, A. Martinetti, L. Celio, G. Procopio, S. Artale, N. Zilembo, M. Di Bartolomeo, E. Seregni, E. Bombardieri, Chromogranin A., neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer, 86(5), 858–865 (1999)
34.
go back to reference S. Gaztambide, F. Vazquez, L. Castaño, Diagnosis and treatment of multiple endocrine neoplasia type 1 (MEN1). Minerva. Endocrinol. 38(1), 17–28 (2013)PubMed S. Gaztambide, F. Vazquez, L. Castaño, Diagnosis and treatment of multiple endocrine neoplasia type 1 (MEN1). Minerva. Endocrinol. 38(1), 17–28 (2013)PubMed
35.
go back to reference Ita.NET Guidelines if Neuroendocrine Neoplasia. 2015 Edition Ita.NET Guidelines if Neuroendocrine Neoplasia. 2015 Edition
Metadata
Title
Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study
Authors
S. Chiloiro
F. Lanza
A. Bianchi
G. Schinzari
M. G. Brizi
A. Giampietro
V. Rufini
F. Inzani
A. Giordano
G. Rindi
A. Pontecorvi
L. De Marinis
Publication date
01-05-2018
Publisher
Springer US
Published in
Endocrine / Issue 2/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1327-0

Other articles of this Issue 2/2018

Endocrine 2/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.